Scientific Program
08:00
Registration
09:00-09:10
Welcome & Opening Remarks
Prof. Dr. Joachim Aerts, Netherlands and Dr. Roberto Ferrara, Italy| Congress Chairs
09:10-10:30
Session 1: Management of Resectable Non-Small Cell Lung Cancer
09:05-09:30
How do we Treat Patients with Oncogene Addicted Resectable NSCLC?
09:30-09:55
How do we Treat Non Oncogene Addicted Resectable NSCLC?
09:55-10:20
What will be the Future Treatment of Non-Oncogene Addicted Resectable NSCLC?
10:20-10:30
Discussion/Q&A
10:30-11:00
Coffee Break, Poster Viewing & Visit the Exhibition
11:00-11:30
Industry Sponsored Symposium
11:30-12:30
Session 2: Novel Diagnostics
11:30-11:55
The Added Value of the Interventional Bronchopist in your MDT
Antoni Rosell
Germans Trias i Pujol University Hospital, Barcelona, Spain
11:55-12:20
The Optimal Workaround for the Pathologist in 2026
12:20-12:30
Discussion/Q&A
12:30-13:30
Lunch Break, Poster Viewing & Visit the Exhibition
13:30-14:30
Session 3: Management of Non Resectable Stage III NSCLC
13:30-13:55
An Eye on the Future: Is Maintenance Anti-PD-L1 Treatment still the Standard of Care?
Noemí Reguart
Hospital Clínic Barcelona, Spain
13:55-14:20
What is the Management of Oncogene Addicted Non Resectable Stage III NSCLC?
14:20-14:30
Discussion/Q&A
14:30-15:00
Short Presentations of Young Investigators
15:00-15:30
Coffee Break, Poster Viewing & Visit the Exhibition
15:30-16:30
Session 4: Small Cell Lung Cancer
15:30-15:55
The Added Value of Immunotherapy in Small Cell Lung Cancer
15:55-16:20
Second Line Treatment in Small Cell Lung Cancer
16:20-16:30
Discussion/ Q&A
16:30
End of Day One
08:30
Registration
09:00-10:30
Session 5: Treatment of Stage IV Non Oncogene Addicted NSCLC
09:00-09:25
The Current Treatment of Stage IV Non Oncogene Addicted NSCLC
09:25-09:50
Novel Checkpoint Inhibitor Options in Stage IV NSCLC
09:50-10:15
What will be the Role of Vaccines and Cellular Therapy?
10:15-10:30
Discussion/ Q&A
10:30-11:00
Coffee Break, Poster Viewing & Visit the Exhibition
11:00-12:00
Session 6: Updates in Thymoma and Mesothelioma
11:00-11:25
How do we Treat Thymoma and Thymic Carcinoma in 2026?
Nicolas Gerard
Institut Curie, Paris, France
11:25-11:50
Developments in Mesothelioma: What will the future bring?
11:50-12:00
Discussion/Q&A
12:00-12:30
Industry Sponsored Symposium
12:30-13:30
Lunch Break, Poster Viewing & Visit the Exhibition
13:30-14:35
Session 7: Genetic Aberrations and New Treatments I
13:30-13:55
What is the Best Treatment Schema for EGFR Mutated Advanced NSCLC?
13:55-14:15
How to Treat ALK Positive Stage IV NSCLC?
Mariana Brandão
Institut Jules Bordet, Brussels, Belgium
14:15-14:35
Treatment in RET + NSCLC
Mihaela Aldea
Gustave Roussy, France
14:35-15:00
Short Presentations of Young Investigators
15:00-15:30
Coffee Break, Poster Viewing & Visit the Exhibition
15:30-16:30
Session 8: Genetic Aberrations and New Treatments II
15:30-15:55
Kras the Untreatable Mutation or Not Anymore?
15:55-16:20
Other Rare Genetic Aberrations
16:20-16:30
Discussion/Q&A
16:30
Closing Remarks & End of Congress
Prof. Dr. Joachim Aerts, Netherlands and Dr. Roberto Ferrara, Italy | Congress Chairs